Jounce Therapeutics (JNCE) option implied volatility elevated, to present data from ICONIC trial at ASCO

Jounce Therapeutics (NASDAQ: JNCE) May call option implied volatility is at 371, June is at 184; compared to its 52-week range of 62 to 186 into announcing data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of an oral presentation at the upcoming 2018 American Society of Clinical Oncology, or ASCO, annual meeting.

You May Also Be Interested In

• SAP SE (SAP) option IV steady into quarter results and outlook
• Nucor (NUE) April weekly option implied volatility elevated into quarter results
• Whirlpool (WHR) April weekly call option implied volatility into quarter results